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Abstract
Background: A hallmark of AIDS progression is a switch of cytokines from Th1 to Th2 in the plasma of patients. IL-12, a
critical Th1 cytokine secreted by antigen presenting cells (APCs) is suppressed by Vpr, implicating it as an important
virulence factor. We hypothesize that Vpr protein packaged in the virion may be required for disabling APCs of the first
infected mucosal tissues. Consistent with this idea are reports that defects in the C-terminus of Vpr are associated with long-
term non-progression.
Principal Findings: Vpr RNA amplified from various sources was electroporated into monocyte-derived DC and IL-12 levels
in supernatants were analyzed. The analysis of previously reported C-terminal Vpr mutations demonstrate that they do not
alleviate the block of IL-12 secretion. However, a novel single conservative amino acid substitution, R90K, reverses the IL-12
suppression. Analysis of 1226 Vpr protein sequences demonstrated arginine (R) present at position 90 in 98.8%, with other
substitutions at low frequency. Furthermore, none of sequences report lysine (K) in position 90. Vpr clones harboring the
reported substitutions in position 90 were studied for their ability to suppress IL-12. Our data demonstrates that none of
tested substitutions other than K relieve IL-12 suppression. This suggests a natural selection for sequences which suppress
IL-12 secretion by DC and against mutations which relieve such suppression. Further analyses demonstrated that the R90K,
as well as deletion of the C-terminus, directs the Vpr protein for rapid degradation.
Conclusion: This study supports Vpr as an HIV virulence factor during HIV infection and for the first time provides a link
between evolutionary conservation of Vpr and its ability to suppress IL-12 secretion by DC. DC activated in the presence of
Vpr would be defective in the production of IL-12, thus contributing to the prevailing Th2 cytokine profile associated with
progressive HIV disease. These findings should be considered in the design of future immunotherapies that incorporate Vpr
as an antigen.
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Human immunodeficiency virus I (HIV- I) possesses many
weapons to evade the immune system of an infected individual.
High sequence variability of the HIV genome allows viral escape
from both humoral and cellular immune responses. HIV
mutations leading to CTL escape are attributed to the failure of
cellular immunity to control HIV infection [1]. Recent studies
demonstrating an inverse correlation between the frequency of
CTL escape via mutation of HIV antigens and the replicative
capacity of the virus further confirm this idea [2]. Mutations that
evade inhibition of compounds comprising HAART regimens are
also well documented.
In addition to direct evasion of immune responses through
mutagenesis, HIV also disturbs cytokine profiles in the plasma of
HIV patients, thereby impeding effective immune responses
against the infection, a feature which is receiving more recognition
[3]. The cytokine response to an invading microorganism is critical
for priming DC-mediated adaptive immune responses and is
subject to tight regulation, particularly in the case of Th-1
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cytokines are detected in the plasma of infected individuals,
however, at later stages of disease, the cytokine profile switches to a
Th 2 profile indicative of a decay in the antiviral immune response
[6]. One of the cytokines associated with Th 1 polarization is IL-
12 and it has been reported that its level is decreased in HIV-
positive patients versus healthy individuals [7]. The association of
IL-12 with productive CD8-mediated cytolytic activity is well
documented in tumor models in vitro and in human clinical trials
[8,9]. Likewise, the impaired immune response to HIV was shown
to be restored in vitro by addition of exogenous IL-12 underscoring
the critical importance of this cytokine [10].
IL-12 is produced by activated antigen presenting cells,
macrophages, and dendritic cells and its level can be modulated
by infection of those cells types with HIV. The viral protein R
(Vpr) is thought to contribute to this effect. Monocyte and DC
cultures incubated in the presence of extracellular Vpr were shown
to downregulate CD80, CD83, and CD86 in these cell types,
blocking their activation and maturation [11]. Another study
supports the observation that Vpr impairs expression of CD80,
CD83, and CD86 costimulatory molecules as well and documents
that Vpr inhibits IL-12 production and upregulates IL-10 cytokine
secretion by DC [12]. That study implicated Vpr as an important
virulence factor in HIV infection and suggested that the
suppressed immune responses may be a consequence of Vpr-
mediated block of IL-12 production by DC. The association of
Vpr mutations with long-term non-progressor (LTNP) status is
also consistent with the idea of Vpr as a virulence factor [13–15].
Approximately 275 molecules of Vpr protein are incorporated
into HIV virions released form productively infected cells [16].
Therefore, Vpr is present during early stages of infection and
available to rapidly exert its function on the cells it first encounters,
DC of the mucosal membranes. While integrity of the a-helices of
Vpr (residues 35–46) is required for efficient packaging into virions
[17]. it is the C-terminus that is implicated in its virulent activity
after release into the infected cell. The mitochondrial domain
located within the C-terminus, specifically amino acid 77, is
implicated in mitochondrion-dependent apoptosis [13,18]. Other
reports indicate that the LXXLL domain located in the C-
terminus is responsible for the suppressive effect on IL-12 via a
glucocorticoid-like mechanism [19].
The present study explored the effect of Vpr expressed from
translation-competent RNA electroporated into DC. Here we
confirm earlier the observations that Vpr suppresses IL-12
secretion by DC and further explore the involvement of the Vpr
C-terminus in IL-12 suppression as an important HIV virulence
factor. Detailed analysis using previously described mutations
within the C-terminus identified a single point mutation, R90K,
which can prevent the IL-12 blockade.
Results
Vpr suppresses IL-12 expression in DC
The first observation of Vpr-mediated IL-12 suppression was
made in a side-by-side comparison of DC electroporated with Vpr
amplified from two different sources; Vpr amplified from the non-
infectious clone, pBKBH10S [20] did not have any negative
impact whereas Vpr amplified from a patient’s plasma (Vpr-2) led
to a several-fold suppression of IL-12 secretion. Alignment of the
Vpr sequences used in this initial experiment revealed that the
amino acid sequence of Vpr allowing secretion of IL-12 in the
culture was truncated at its C-terminus (Figure 1).
In order to confirm this initial observation and rule out the
possible contribution of other previously reported suspect amino
acids in positions 15, 37, and 55, the experiment was repeated
using full-length and truncated Vpr generated from a single
template (Vpr-2), as described in materials and methods. The
levels of secreted IL-12 were measured in supernatants of DC
electroporated with either full-length or truncated Vpr RNAs
(Figure 2). In this experiment, IL-12 secretion in the supernatants
of DC electroporated with RNA encoding full-length VPR
(0.25 mg per 10
6 DC) is suppressed by 75% compared to those
electroporated with control RNA encoding GFP. Also, electropo-
ration of DC with even higher amounts of truncated Vpr RNA
(1 mg per million of DC) did not result in substantial suppression of
IL-12 secretion. Since electroporation with a lower amount
(0.25 mg per 10
6 DC) of full-length Vpr resulted in substantial
inhibition of IL-12 secretion, a higher amount of RNA (e.g.,1mg
per 10
6 DC) was not tested in this experiment.
The absolute level of IL-12 secreted into the supernatant is
highly variable among independent healthy donor cells [21,22].
To control for this variability, the data in each experiment are
Figure 1. Alignment of amino acid sequence of Vpr amplified from isolate Vpr-2 and non infections plasmid pBKBH10S. Alignment and
alignmentreportwere generatedusingLasargene software(DNAstar). Aminoacids 15, 37,and55,outside oftheC-terminalregionwhichdifferbetween
the two Vpr proteins are highlighted by grey boxes. The last grey box (amino acid 74) indicates the divergence of the two sequences at the C-termini.
doi:10.1371/journal.pone.0005853.g001
R90K Vpr and IL12 in DC
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were electroported with the inert RNA encoding GFP. These data
confirm that full-length Vpr suppresses IL-12 expression and the
domain responsible for the inhibition is located within amino acids
79–96.
Vpr expressed from transfected RNA does not lead to
maturation defects in DC
Previous reports suggested that Vpr blocks the maturation status
of the DC as indicated by the change in expression of the surface
phenotype markers CD80, CD83 and CD86 [11,12]. Expression
of these surface markers as well as viability were examined in DC
electroporated with low (0.25 mg) or high (1 mg) masses of Vpr
RNA at per 10
6 DC (Table 1).
The mean fluorescent intensity for staining with the antibodies
correlates with the level of protein expressed per cell and did not
vary between the different conditions in this experiment (data not
shown, detailed analysis presented in Figure 3).
These experiments demonstrate that phenotypic maturation
markers expressed on DC are not affected when Vpr is expressed
from translation-competent RNA. This observation is inconsistent
with previous reports [11,12]. The difference may be due to the
different platforms utilized for Vpr expression. This study utilized
translation-competent Vpr RNA under conditions that optimize
cytoplasmic delivery whereas Majumder and colleagues employed
HIV-1 Vpr+ or HIV-1 Vpr2 viruses for the infection of the DC
[12] and Muthumani and colleagues used cultures treated with
purified recombinant Vpr protein [11].
Amino acid R77 and the LXXLL domain are not
responsible for suppression of IL-12 cytokine secretion
The data described above demonstrates that the Vpr C-terminal
domain is responsible for the IL-12 suppressive effect and provides
an initial analysis of which amino acids may be responsible for the
IL-12 blockade with emphasis on those already described in
literature. Argenine in position 77 of Vpr is reported to bind to
adenine nucleotide translocator (ANT) expressed in the mito-
chondrial membrane causing its depolarization which leads to the
induction of a caspase-dependent pathway and eventual apoptosis.
At least two reports link the R77Q substitution in Vpr with long-
term non-progression (LTNP) of HIV-infected patients [13,18].
The HIV clone, p98CN009.8, contains Vpr with a Glutamine (Q)
in position 77 and we used it to prepare Vpr RNA encoding Q77.
In addition, we created the reverse substitution, Q77R in the
p98CN009.8 background. If the R77 residue is responsible for the
IL-12 suppression it is expected that Q77 would relieve the IL-12
suppression and the reverse mutation Q77R will have the opposite
effect.
We also evaluated the contribution of the LXXLL domain
found within the C-terminus of Vpr. The GR-like LXXLL motif is
implicated in suppression of IL-12 production in monocytes[19].
This study reported that through the involvement of the LXXLL
coactivator signature motif, Vpr acts as a potent coactivator of the
glucocorticoid receptor pathway and IL-12 is one of the targets
regulated by that pathway. The core LXXLL motif in ligand-
bound nuclear hormone receptors is necessary and sufficient to
bind the cellular transcriptional co-activator proteins, a function
known to be disrupted by the AXXLL mutation [23]. An AXXLL
containing Vpr mutant was created in the background of the
p98CN009.8 Vpr.
To test the impact of these mutations on the ability to regulate
IL-12 secretion by DC, all of the RNAs amplified from Vpr
mutants were transfected into DC. IL-12 expression profiles in the
supernatants of the transfected DC is presented on Figure 3,
panel A. Analysis of cell surface marker expression is presented in
Figure 3, panels B and C. Cytokine levels in DC culture
supernatants collected 24 hrs post-electroporation indicate that
RNA encoding the truncated Vpr amplified from template Vpr-2
do not inhibit IL-12 secretion and is similar to the control
condition where cells were electroporated with only control GFP
RNA. As previously observed, truncated Vpr amplified from Vpr-
2 relieved the IL-12 suppression. The full-length Vpr RNA
amplified from p98CN009.8 also suppressed the IL-12 secretion.
This indicates that Arginine in position 77 is not involved in the
regulation of the IL-12 cytokine pathway. Since amino acid 77 is
not involved, it was not surprising that the reverse mutant Q77R
did not differ from the wild-type p98CN009.8 and suppressed IL-
12 secretion as well.
Our observation that disruption of the core LXXLL motif did
not result in suppression of IL-12 secretion is in contrast to
reported observations using purified Vpr protein in monocyte
cultures. The observed differences of IL-12 levels may be due to
the differences in the two experimental systems. This experiment
also confirmed our original observation that the MFI of the
maturation markers, CD80, CD83, and CD86 are not significantly




6 DC) % CD80* % CD83* % CD86* Viability**
1 mg eGFP control 87 84 100 100
1 mg VPR, trunc 96 94 100 104
0.25 mg VPR, trunc 96 94 100 104
0.25 mg VPR, full 96 91 100 96
*Cell surface phenotype of the DC is expressed in percent positive cells staining
with the indicated antibody.
**Viability at 24 hrs post electroporation time point is expressed in percent
relative to control DC transfected with eGFP RNA alone.
doi:10.1371/journal.pone.0005853.t001
Figure 2. Full length but not truncated Vpr inhibits IL-12
secretion by DC. Levels of IL-12 detected in supernatants of DC
cultures 24 hrs post-electroporation. Black bar GFP, grey bar: 1 mgo f
RNA of Vpr truncated version pattern bar: 0.25 mg of full length Vpr (Vpr
2) were electroporated per million of DC. Condition when GFP RNA was
electroporated alone is taken as maximum potential level of IL-12
cytokine secretion in each experiment.
doi:10.1371/journal.pone.0005853.g002
R90K Vpr and IL12 in DC
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the percentage of cells expressing those markers differ between
each CD40L DC-matured population (Figure 3, panel C).
Expression of AXXLL and R77Q Vpr RNAs was confirmed in
vitro (Data not shown). In addition continuous suppression of IL-
12 in the DC electroporated with the AXXLL and R77Q Vpr
RNA indirectly suggests lack of those mutations on the expression
of Vpr in DC. The lower levels of maturation markers expressed
by the GFP RNA-electroporated control cells was due to the lack
of co-transfection with CD40L RNA, which is required to achieve
full DC maturation in this system.
The C-terminal domain structure is important for Vpr-
mediated suppression of IL-12 secretion by DC
Given than none of the mutations tested above demonstrated
any impact on IL-12 secretion, we next created a new series of
mutations within the C-terminal region: R90K as well as deletion
of the last three amino acid residues, eliminating both S94 and S96
(DSRS). These residues are reported to be important for
transactivation of Vpr and induction of G2 cell cycle arrest
(reviewed in [24]). The R90K and DSRS mutants were created in
the background of the p98CN009.8 clone. The RNAs transcribed
from these cDNA fragments were electroporated into DC followed
by an IL-12 Elisa assay on 24 hr supernatants. As a control the
RNAs were electroporated in the absence of any Vpr RNA
(Figure 4). In this experiment the use of the C-terminal truncated
form of Vpr versus full-length (WT) Vpr (1 mg of RNA per 10
6
DC) demonstrated relief of IL-12 suppression. More interestingly,
cultures of DC electroporated with R90K Vpr had levels of IL-12
comparable to those observed using the C-terminal Vpr truncation
or in the complete absence of Vpr RNA (GFP control). The same
result was obtained with p98CN009.8 Vpr RNAs and its mutants
transfected into DC at 5 mg RNA per 10
6 DC (data not shown).
The data also repeated with all Vpr mutants created in the Vpr-2
genetic background (data not shown). The viability of the DC
cultures post electroporation was 93–94% for all conditions in this
experiment; therefore the different IL-12 levels measured in the
supernatants were not due to different numbers of viable cells in
the cultures. The percent of viable dendritic cells vary from
experiment to experiment because of different donor material used
to generate the DCs. Therefore the viability data should be
derived from intra assay conditions. These data clearly show that a
single conservative amino acid substitution, R90K, in full length
Vpr prevents the IL- 12 blockade in DC.
C-terminal deletion or R90K mutation leads to Vpr
protein degradation via ubiquitin-dependent pathway
In order to confirm that proteins were expressed from wild-type,
truncated and R90K mutant RNAs we conducted studies using
Western blot analysis. First, translation of Vpr products was
confirmed using an in vitro translation system. The Western blot
analysis results indicate that all RNAs produced polypeptide
products in vitro migrating at an expected molecular weight and
recognized by a specific anti-Vpr polyclonal antiserum (Figure 5,
panel A). These data indicated that the presence of the C-terminal
truncation or R90K mutation do not impact on the ability of the
ribosomal machinery to translate Vpr RNAs.
The next experiment analyzed the Vpr protein expression levels
in DC that were electroporated with 5 mg per 10
6 DC of each Vpr
RNA. A higher mass of RNA was chosen because of the low
sensitivity of the Western blot analysis and the lack of a strong
signal obtained with the lower mass of 1 mg of RNA per 10
6 DC
(data not shown). The IL-12 expression data obtained with either 1
or 5 mg of RNA were comparable. A specific signal was obtained
Figure 3. Effect of mutants on IL-12 secretion and immunophenotype. Analysis of IL-12 secretion profile and phenotype of the DC
transfected with Vpr mutants in position 77 and LXXLL C-terminal motif. Full-length Vpr from either Vpr 2 or p98CN009.8 plasmid or its mutants, no
Vpr with CD40L RNA (control) or GFP alone were electroporated into DC at amount of one microgram of RNA per million of DC. Panel A: levels of IL-
12 cytokine detected in DC supernatants 24 hrs post- electroporation. Panel B: percent positive cells stained with specific anti CD80, anti CD83 and
anti CD86 antibody. Panel C: mean fluorescent intensity of signal detected with specific antibody.
doi:10.1371/journal.pone.0005853.g003
R90K Vpr and IL12 in DC
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B) however, the expression levels of the truncated Vpr or R90K
mutant are decreased dramatically by comparison. Since all of the
proteins were efficiently translated in vitro (Figure 5, panel A), the
differences in the expression levels in DC cannot be explained by
the differential translational competence of the RNAs. To further
explore this, we repeated the analysis and allowed the DC to
recover post-electroporation in the presence of a ubiquitin
degradation pathway inhibitor, lactacystin (Figure 5, panel C).
In the presence of lactacystin, there was an accumulation of the
Vpr-specific signals using lysates of DC electroporated with
truncated Vpr or the R90K mutant. Although all Vpr RNAs
are translated in the DC, both the truncated form and the R90K
mutant are rapidly degraded and the lack of their expression
persistence may explain their non-interference with IL-12
secretion. In the presence of the inhibitor of ubiquitin-mediated
degradation, the levels of the truncated form of Vpr and the R90K
mutant are elevated.
The R90 residue is highly conserved in Vpr and R90K is
the only substitution tested which relieves the IL-12
suppression
Next we examined the frequency of amino acid substitutions at
position 90 of the Vpr protein in the Los Alamos HIV sequence
database. Full-length Vpr protein sequences (n=1,226) were
aligned and the identity and frequency of the amino acid in
position 90 was examined (Table 2). At the time of this analysis,
the Los Alamos sequence database did not list any Vpr protein
with K (lysine) in a position 90. 98.78% of all analyzed sequences
contained R (arginine) in position 90 indicating that this amino
acid is highly conserved. The frequency of amino acid substitu-
tions in position 90 is less than 0.5%.
The impact of all amino acid substitutions reported in the Los
Alamos HIV sequence database at Vpr position 90 were next
examined in the IL-12 secretion assay. The RNA encoding the
two most frequently reported substitutions, G and S, in the
background of p98CN009.8 were created and transfected into DC
followed by measurement of IL-12 secretion by Elisa. R90 and
R90K were also used in the same experiment as controls
(Figure 6). Of all amino acid substitutions tested in position 90,
only the R90K relieves the suppression of IL-12. Interestingly, Vpr
RNA encoding for amino acids substitutions G and S in position
90 suppress IL-12 secretion to levels comparable or even lower
than the wild-type R90 Vpr.
Discussion
HIV Vpr has been shown to negatively regulate the function of
antigen presenting cells such as macrophages and dendritic cells
[11,12]. Our study, using a very different expression system,
translation competent RNA, independently confirms the observa-
tion that Vpr blocks production of the Th1 cytokine, IL-12, which
is required for CTL activation [8,9]. We also demonstrate that
upregulation of phenotypic cell surface markers of DC maturation
(i.e., CD86, CD80, CD83) in the absence of IL-12 secretion
indicates that upregulation of those molecules alone is not
sufficient for the induction of IL-12 secretion. Levels of IL-12
are decreased in HIV-positive individuals versus healthy volun-
teers [7] and Th-2 cytokines predominate in the plasma of late-
stage AIDS patients [10]. The reduced cellular immunity may be
explained by the blocking of IL-12 secretion by antigen presenting
cells such as DC expressing Vpr. This idea is supported by a study
in rhesus macaques where inclusion of the Vpr accessory gene in
an experimental plasmid-based vaccine containing Nef antigen
markedly reduced Th1 type responses compared to the vaccine
containing only the Nef antigen, which led to decreased CD4 T
cell counts and increased viral loads [25].
Negative effects attributed to Vpr manifested by downregulation
of costimulatory molecules and suppression of IL-12 secretion
have been reported. In contrast to previous reports, our study did
not confirm the observation of CD83, CD86, and CD80
downregulation. This may be the due to the difference in delivery
system of Vpr to the DC. The study by Muthumani et. al [11] used
Vpr recombinant protein which was co-incubated with the DC
and Majumder et. al. used DC transfected with HIV Vpr+ proviral
constructs [12] whereas in our study Vpr expression is achieved
using translation-competent RNA electroporated into the DC.
The Vpr RNA is translated in the cytoplasm of the DC and is a
highly homogeneous expression system which bypasses the need
Figure 4. Vpr R90K mutation restores IL-12 secretion from DC. Analysis of IL-12 secretion profile and phenotype of the DC transfected with
Vpr mutants in C-terminal region. Full-length Vpr from p98CN009.8 plasmid or its mutants, or no Vpr with CD40L RNA (control) were electroporated
into DC at amount of one mg of RNA per million of DC. Panel A: levels of IL-12 cytokine detected in DC supernatants 24 hrs post- electroporation.
Panel B: mean fluorescent intensity of signal detected with specific antibody recognizing CD80, CD83, and CD86 surface markers. Viability of cells
24 hrs post electroporation with WT, D2C term, R90K DSRS or GFP RNAs were 93%, 93%, 94% 94% and 94% respectively.
doi:10.1371/journal.pone.0005853.g004
R90K Vpr and IL12 in DC
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Vpr to different subcellular compartments compared to other
expression methods or the provision of exogenous Vpr protein. As
a consequence, variable effects may be observed.
Detailed analysis of the C-terminal region did not support any
previously reported mutations in the C-terminal region as
modulators of IL-12 expression levels. Mirani et al, desribed
downregulation of IL-12 production via a GR-like function in
cultured monocytes by adding purified recombinant Vpr protein
and modulating the effect on IL-12 with the GR antagonist,
RU486 [19]. The direct Vpr GR-like effect on IL-12 secretion in
our system was elucidated by mutating the LXXLL motif to
AXXLL which is reported to inactivate the nuclear receptor
function. However, side-by-side comparison of the DC electropo-
rated with two Vpr RNAs encoding either a functional LXXLL
motif or containing the inactivating mutation, AXXLL, did not
demonstrate any difference in the ability to express the IL-12.
Additionally, the R77Q mutation of Vpr is thought to be
associated with long-term control of HIV infection [13,14]. If
preservation of IL-12 expression is associated with the LTNP
Table 2. Analysis of frequency and type of amino acid
substitutions in position 90 of 1226 full length Vpr sequences
found in Los Alamos National Database.
Amino acid
in Vpr position 90
Total number
reported











Figure 5. Vpr mutants have enhanced ubiquitin-mediated degradation leading to low steady-state levels in DC. Analysis of Vpr
expression from RNA template in vitro and in DC. Panel A:Western blot analysis of in vitro-translated full-length Vpr RNA or its mutations as indicated.
NTC: control reaction performed in the absence of an RNA template. Panel B: Western blot analysis on lysates of DC electroporated with full length
Vpr RNA or its mutations. After electroporation DC were incubated for four hours in the absence or presence of lactacystin at 10 mM final
concentration as indicated. IVT VPR Ctrl: in vitro-translated full-length Vpr protein used as a positive control in Western blot assay. RNAs used for
electroporation of DC are indicated on the top.
doi:10.1371/journal.pone.0005853.g005
R90K Vpr and IL12 in DC
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secretion assay. However, our data show that in a direct
comparison of RNA encoding wild-type R77 and the Q77
mutant, in otherwise identical Vpr amino acid backgrounds, no
difference in IL-12 secretion is observed.
Interestingly, a high rate of Vpr mutations and other defects in
the C-terminal domain are described in LTNP cohorts [26–28].
The deletion of the last three amino acids did not change the
ability of Vpr to modulate IL-12 secretion, however, the R90K
substitution revealed complete reversal of IL-12 suppression,
restoring the level to that observed with the truncation of the entire
C-terminal Vpr domain. Interestingly, sequence analysis of Vpr
within the Los Alamos Database revealed no such mutants. The
analysis revealed that other amino acid substitutions such as R90G
and R90S are present, but at a cumulative frequency not
exceeding 1.3%. Reports of the R90K substitution were found
by a manual search of the literature [26,29] and in both cases this
mutation was isolated from a patient exhibiting an LTNP
phenotype. It is therefore possible to envision that strains of
HIV encoding R90K have lower virulence. Virus encoding Vpr
R90K may be unable to block IL-12 secretion. IL-12 cytokine is a
component of LTNP phenotype in HIV infected individuals, and
is a common feature with healthy individuals. Our analysis of
amino acids reported at position 90 indicated that R (arginine) is
highly conserved. None of the amino acids reported in this
position tested in our assay relieve IL-12 suppression and the
R90K substitution is the only substitution which restored the Il-12
secretion profile. These data taken together suggest that HIV
naturally selects for a sequence encoding for amino acids which
suppress IL-12 secretion by DC and against the mutation(s) which
relieves this suppression.
NMR structural analysis of the C-terminal region of Vpr
suggests it has a dimeric structure [30,31] which is confirmed
experimentally [30]. Studies of the C-terminus predicted the
dimeric structure of the full length Vpr protein in solution and the
dimerization was postulated to be biologically relevant. Our data
demonstrate that the intact C-terminus is important for the
suppression of IL-12. It would be of interest to explore whether the
R90K amino acid substitution causes disruption of the Vpr
dimeric structure. The amino acids previously described by
Schuler et al resulting in the disruption of the dimers do not
involve amino acid position 90 [30]. Our study uncovers the
mechanism of how the R90K substitution allows for IL-12
secretion in the DCs.The R90K substitution perhaps is recognized
as a defect and directs Vpr for rapid degradation. This would
suggest that the R90K substitution is not directly involved in
activation of the IL-12 secretion pathway; rather the R90K
substitution alleviates the suppressive effect of wild-type and other
amino acids found in this position through the reduction of
intracellular Vpr protein levels. In summary, our study documents
a single amino acid substitution which is not found in most of the
reported HIV genomes. We predict that selective pressure exists to
preserve an amino acid at position 90 which supports IL-12
suppression. The R90K substitution relieves IL-12 suppression
and is selected against, since other amino acids more distantly
related to R than K are observed in infected subjects. This finding
provides further support for Vpr as a virulence factor during HIV
infection. The DC matured in the presence of Vpr are defective in
the production of IL-12 and eventually lose their ability to
orchestrate productive T cell responses thus mediating, at least in
part, the switch from Th1 to Th2 cytokine production which is a
hallmark of progression to AIDS.
The physiologic contribution of Vpr to natural viral infection
and persistence is perplexing. The negative influence of IL-12
blockade on adaptive antiviral immunity is in apparent conflict
with studies which highlight Vpr as a dominant immune target.
Cytotoxic CTL responses against Vpr in HIV infection are well
documented [32] and Vpr is described as an antigen to which
CTL responses are preferentially directed [33]. We recently
reported a novel multiplex RT-PCR-based approach for the
generation of autologous HIV antigens, including Vpr, for the
immunotherapy of HIV-infected individuals [34]. Our experi-
ments demonstrated Vpr-specific stimulation of CD8 T cell
proliferation by DC expressing Vpr [34]. However, the PCR-
amplified portion of Vpr used in that study lacked the C-terminal
20 amino acids, thus allowing Vpr expression without IL-12
suppression. The data presented in this manuscript provides a
molecular basis for the generation of anti-Vpr
Figure 6. Analysis of amino acid substitutions reported in Los Alamos database on Vpr ability to modulate IL-12. Vpr clones carrying
the most frequently reported amino acid substitutions in position 90 of 1,226 full-length Vpr sequences in the Los Alamos National Database were
cloned and tested for their ability to modulate IL-12 secretion by the DC. Vpr wild-type (WT), VPR lacking C-terminus (DCterm), Vpr R90K, Vpr R90G,
Vpr R90S RNAs or GFP RNA alone were electroporated into DC and levels of IL-12 detected in DC supernatants 24 hrs post-electroporation. Viability of
cells electroporated with WT and mutant Vpr RNA was 71–85% whereas the viability of a GFP RNA-electroporated DC was 76%.
doi:10.1371/journal.pone.0005853.g006
R90K Vpr and IL12 in DC
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5853CD8
+CD28
+CD45RA
2 effector memory T cells, which is known
to require IL-12 secretion [35]. Importantly, for immunothera-
peutic design, the truncation of Vpr protein to amino acids 1–72
preserves all currently described HLA epitopes documented in the
HIV immunology database (http://www.hiv.lanl.gov/content/
immunology/maps/ctl/Vpr.html) located between amino acids 7
and 70 and does not compromise the ability of the DC expressing
the truncated Vpr to secrete IL-12. The ability to utilize Vpr as a
component of experimental immunotherapeutics may be partic-
ularly important. since a systematic bioinformatic analysis of the
Clade C HIV proteome revealed that HIV-1 mutations in Vpr
which confer escape from CTL recognition can result in the lowest
viral fitness compared to those directed against any other HIV
protein [2]. These observations should figure prominently in the
choice of antigens for use in anti-HIV immunotherapeutic design
and consideration should be given to preserving or restoring IL-12
secretion.
Materials and Methods
Cellular materials used to generate the DCs
All materials used in the studies described in this paper collected
from healthy volunteers at Lifeblood Biological Services, LLC.
The company operates under FDA establishment license to collect
normal subjects for products for research use only. The collection
is preceded by signing of a written consent form.
Generation of DC and cellular analyses
Generation, maturation, and electroporation DC from healthy
volunteers were carried out according to the CD40L DC
maturation protocol described by Calderhead et. al [36]. The
electroporated mass of RNA is indicated in each experiment as mg
per million DC. The phenotype of the DC were evaluated by
staining with phycoerythrin (PE)-conjugated mouse anti-human
antibodies: CD80 (L307.4), CD83 (HB15e), and CD86 (FUN-1).
Isotype matched mouse IgG1 (MOPC-21) was used as a negative
control. All antibodies were sourced from BD Biosciences, San
Jose, CA. Cell staining and Enzyme-linked Immunosorbent Assay
(ELISA) for IL-12 levels in DC supernatants was carried out as
previously described [36] Cells electroporated with each RNA
were incubated in duplicates and measurements were performed
in undiluted and diluted supernatants. Values were obtained using
all conditions falling within the IL-12 detection range corrected for
the dilution factor.
Cell viability was determined using Caltag Counting Beads
(Invitrogen) and propidium iodide (to identify dead cells) both pre-
and post-transfection. Cells were diluted to 1610
6 cells/ml
following transfection and incubated overnight. Cells were
harvested 18–22 hours post electroporation and supernatants used
for IL-12 determination while the cells were stained for the
maturation markers CD80, CD83 and CD86.
Analysis of Vpr translation products by Western Blot
analysis
In vitro-translated products of Vpr RNA were generated using a
Wheat Germ Lysate translation system (Promega). Analysis of Vpr
translation was by Western blot with DC lysates prepared from
cells electroporated with Vpr or control RNA after 4 hours post-
electroporation with or without lactacystin at 10 mM final
concentration. Total protein was extracted from DC using M-
PER mammalian protein extraction reagent (Pierce) according to
manufacture’s recommendations. Protein concentration was
determined by the Bradford assay method (Bio-Rad). 40 mgo f
total protein extract from DC or a 1 mL aliquot of in vitro
translation reaction product were separated by SDS PAGE and
transferred to PVDF membrane. The membrane was incubated
with a 1:500 dilution of Rabbit polyclonal antisera HIV-1NL4–3
Vpr Antiserum (1–40) from the NIH AIDS Research & Reference
Reagent program followed by incubation with Peroxidase-labeled
anti-rabbit secondary antibodies (Amersham). The signal was
developed using ECL Plus reagents (Amersham) and scanned
using a Storm imager.
Amplification of Vpr RNA from infectious plasma
RNA extraction from plasma and amplification of sequences
containing the coding region of Vpr were performed as described
previously [34]. The primary PCR product was taken into a
secondary PCR reaction containing primers modified by insertion
of a T7 promoter sequence and a 64T nucleotide sequence.
Generation of full-length Vpr or its truncation was performed
using alternative reverse primer groups. The primers anneal to
upstream (64T T trunc) or downstream (64T full) region of
naturally occurring the Vpr Stop codon, thus leading to
amplification of truncated or full length Vpr, respectively.
Sequences of Vpr primers used in the secondary PCR reaction
are listed in Table 3.
Amplification of Vpr from a non-infectious clone, pBKBH10S,
was performed using single forward and reverse primers compli-
mentary to the template determined by sequence analysis. [20].
Generation of C-terminal mutant clones of Vpr
Mutations in position 77 were generated using the non-
infections plasmid, p98CN009.8, containing the near full-length
HIV genome [37]. This clone contains a naturally occurring Q77
residue. The Q77R amino acid substitution was constructed using
PCR amplification with primers encoding the mutation listed in
Table 4. The PCR fragment amplified from the p98CN009.8
template was gel purified and subcloned into a pUC19 vector.
The AXXLL mutation was introduced by a fusion PCR
approach. First, the template plasmid, Q77R p98CN009.8, was
amplified using 2 PCR reactions with the four primers listed in
Table 5. The mixture of the two PCR fragments served as a
template for the second PCR reaction using primers 59 VPR
BamHI and 39 VPR Pst I only (Table 5). The fragment was
subcloned into a pUC19 vector. The presence of all mutations was
verified by sequence analysis.
Table 3. Sequences of Vpr primers used in the secondary PCR
reaction to generate full length or truncated at C terminus
Vpr.
Name 59–39 sequence
T7 F 1 TAATACGACTCACTATAGGGAGACCACCATGGAACAAGCCCCAG
T7 F 1.1 TAATACGACTCACTATAGGGAGACCACCATGGAACAAGCCCCGG
64T full 1 (T)64GCAGTTGTAGGCTGACTTCC
64T full 1.1 (T)64GCAGTTGTAGGCTGACTCCC
64T full 1.2 (T)64GCAGTTGTAGGCTGGCTTCC
64T trunc 1 (T)64AGCGAACAAACAGTAGTTGTTGCAG
64T trunc 1.1 (T)64AGCGAACAAACAGTAGTTGTTGCAA
64T trunc 1.2 (T)64AGCGATCAAACAGCAGTTGTTGCAG
64T trunc 1.3 (T)64AGCGAACAAACAGTAGTTGTTGAAG
64T trunc 1.4 (T)64AGCGATCAAACAGTAGTTGTTGCAG
doi:10.1371/journal.pone.0005853.t003
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PCR fragments containing T7 Promoter sequences or linearized
pUC19 plasmid containing various Vpr mutants were in vitro-
transcribed using a mMessage mMachine T7 Ultra kit (Ambion)
according to the manufacturer’s recommendation. The RNA was
purified using RNeasy columns (QIAGEN) and eluted in water.
The RNA was stored frozen in liquid nitrogen in single use
aliquots.
Analysis of frequency of amino acid substitution in a
position 90 of Vpr proteins
Amino acids of C-terminus of Vpr protein were aligned using
HIValign tool at Los Alamos HIVsequence database using7 amino
acids as a query (http://www.hiv.lanl.gov/content/sequence/
HMM/HmmAlign.html) total number of returned aligned se-
quences was 1,226. The identity and frequency of amino acid
substitutions in position 90 were calculated using Microsoft Excel.
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